ClassID:

97022

C07K14/685 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin; Melanocyte-stimulating hormone [MSH] Alpha-melanotropin

Recent Application in this class:
#1
20260151434
2026-06-04

COMPOSITIONS FOR THE TREATMENT OF DISEASE

#2
20250195606
2025-06-19

METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS

#3
20250188124
2025-06-12

PEPTIDE COMPOSITIONS

#4
20220298219
2022-09-22

Cyclic peptide analogs of melanocortin and amanitin and methods of making such

#5
20220273766
2022-09-01

ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF

#6
20220226425
2022-07-21

METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS

#7
20220062387
2022-03-03

Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

#8
20210169970
2021-06-10

Method of treating melanocortin-4 receptor pathway-associated disorders

#9
20210040155
2021-02-11

Peptide compositions

#10
20210024605
2021-01-28

Cyclic peptide analogs of melanocortin and amanitin and methods of making such

#11
20200095303
2020-03-26

Pharmaceutical compound

#12
20190309022
2019-10-10

Modulators of melanocortin receptors

#13
20190282716
2019-09-19

Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

#14
20190216887
2019-07-18

Melanocortin receptor-specific peptides

#15
20190092815
2019-03-28

Peptide compositions

#16
20190030134
2019-01-31

Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

#17
20190030129
2019-01-31

ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF

#18
20180371048
2018-12-27

Fusion protein for alpha-melanocyte stimulating hormone and preparation method and use thereof

#19
20180319843
2018-11-08

Compositions and methods for treating central nervous system (CNS) disorders and mood disorders

#20
20180311309
2018-11-01

Method of treating melanocortin-4 receptor pathway-associated disorders

#21
20180311304
2018-11-01

Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N

#22
20180215790
2018-08-02

METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS

#23
20180140677
2018-05-24

Enhanced melanoma cancer prevention by novel melanotropins

#24
20180099994
2018-04-12

Nucleic acid construct

#25
20180094039
2018-04-05

Pharmaceutical compound

#26
20180008676
2018-01-11

Therapy for vitiligo

#27
20170313756
2017-11-02

Peptide analogs of alpha-melanocyte stimulating hormone

#28
20170174738
2017-06-22

Alpha- and gamma-MSH analogues

#29
20170020953
2017-01-26

Methods for the treatment of depression and anxiety

#30
20170020952
2017-01-26

Methods for the treatment of central nervous system (CNS) disorders and mood disorders

#31
20160375158
2016-12-29

Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

#32
20160318977
2016-11-03

Melanocortin receptor-specific peptides

#33
20160175384
2016-06-23

Melanotropin ligands for skin care

#34
20160074469
2016-03-17

Alpha-and gamma-MSH analogues

#35
20160046688
2016-02-18

Peptide analogs of alpha-melanocyte stimulating hormone

#36
20160024171
2016-01-28

Engineered nucleic acids and methods of use thereof

#37
20160017001
2016-01-21

Peptide compositions

#38
20150010557
2015-01-08

Method for delivering alpha-melanocyte stimulating hormone mimetibody composition comprising propylene glycol for intranasal administration to the central nervous system

#39
20140357575
2014-12-04

Melanocortin receptor-specific heptapeptides

#40
20140155328
2014-06-05

Alpha- and gamma-MSH analogues

#41
20140147385
2014-05-29

Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

#42
20130303452
2013-11-14

Peptide analogs of alpha-melanocyte stimulating hormone

#43
20130217628
2013-08-22

Method for preventing or reducing acute renal failure by administration of therapeutically active α-MSH analogues

#44
20120226018
2012-09-06

Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2

#45
20120178701
2012-07-12

Melanocortin receptor-specific peptides

#46
20120077957
2012-03-29

Lactam-bridged melanocortin receptor-specific peptides

#47
20120065252
2012-03-15

Engineered nucleic acids and methods of use thereof

#48
20120021973
2012-01-26

Peptides for Treatment of Obesity

#49
20110312878
2011-12-22

PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

#50
20110130705
2011-06-02

THERAPY FOR VITILIGO

#51
20110129462
2011-06-02

Intranasal administration of active agents to the central nervous system

#52
20110065652
2011-03-17

Melanocortin receptor-specific peptides for treatment of sexual dysfunction

#53
20110033380
2011-02-10

Compounds and methods for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

#54
20100278845
2010-11-04

Fusion proteins of alpha-MSH derivatives and Fc

#55
20100173835
2010-07-08

Peptides for Treatment of Obesity

#56
20100173834
2010-07-08

CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS

#57
20100121027
2010-05-13

Cyclic peptide compositions for treatment of sexual dysfunction

#58
20090304586
2009-12-10

Chelating agent conjugated α-MSH peptide derivatives, preparation method thereof and composition for diagnosis and treatment of melanoma comprising the same as an active ingredient

#59
20090297444
2009-12-03

Peptide analogs of alpha-melanocyte stimulating hormone

#60
20090232838
2009-09-17

Ligands of melanocortin receptors

#61
20090203581
2009-08-13

Novel Peptides for Use in the Treatment of Obesity

#62
20090136505
2009-05-28

Intranasal Administration of Active Agents to the Central Nervous System

#63
20090069242
2009-03-12

Therapeutically active alpha MSH analogues

#64
20090011997
2009-01-08

Bifunctional hormone having alpha-MSH activity and natriuretic peptide activity and uses thereof

#65
20080242600
2008-10-02

Backbone Cyclized Melanocortin Stimulating Hormone (Alpha Msh) Analogs

#66
20080234467
2008-09-25

Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

#67
20080227954
2008-09-18

Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

#68
20080171849
2008-07-17

Peptide Cyclisation

#69
20080139785
2008-06-12

Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

#70
20080015152
2008-01-17

Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

#71
20070293418
2007-12-20

Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

#72
20070077195
2007-04-05

N and/or N derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH)(CO)] by coordination

#73
20070027086
2007-02-01

Melanocortin 1 receptor selective compounds

#74
20070015257
2007-01-18

Alpha-MSH related compounds and methods of use

#75
20060111281
2006-05-25

Cyclic peptide compositions for treatment of sexual dysfunction

#76
20060104966
2006-05-18

Transglutaminase linkage of agents to tissue

#77
20060063699
2006-03-23

Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

#78
20050282763
2005-12-22

Methods of treating bladder disorders

#79
20050239170
2005-10-27

α-MSH related compounds and methods of use

#80
20050222014
2005-10-06

Multiple agent therapy for sexual dysfunction

#81
20050124551
2005-06-09

Use of KPV tripeptide for dermatological disorders

#82
20050037951
2005-02-17

Composition and methods for treatment of sexual dysfunction

#83
20050026827
2005-02-03

Octapeptide bombesin analogs

#84
20050025723
2005-02-03

Sunburn treatment and sunburn prevention method